Mirvat Alasnag interviews Jacob Eifer Møller about the results of the DANGER-shock Trial which he presented at the #ACC24
Implantation of microaxial flow pump post-heart attack significantly boosts survival in patients with STEMI-related cardiogenic shock, though with increased complications. The trial's positive findings indicate potential routine use in severe cases, with benefits persisting beyond 30 days, albeit with notable risks.
More news about the ACC.24 on PCRonline: www.pcronline.com/News/Whats-...